Prime Medicine stock jumps after FDA clears PM647 gene-editing trial for alpha-1 antitrypsin deficiency
Prime Medicine shares jumped in after-hours trading after the FDA cleared PM647 for first-in-human testing, moving a one-time gene-editing therapy for alpha-1 antitrypsin deficiency from promising animal data into the much harder test of clinical development.